HCA Healthcare Delivers Solid Q1 2026 Results: Key Metrics, Guidance, and Shareholder Updates

Date: April 24, 2026

Ticker: NYSE: HCA

Summary of Financial and Operating Results

• Revenues: Rose by 4.3% year-over-year to \$19.109 billion in Q1 2026 (from \$18.321 billion in Q1 2025).
• Net Income Attributable to HCA Healthcare, Inc.: Slight increase of 0.6% to \$1.620 billion (\$7.15 per diluted share, up 10.9%).
• Adjusted EBITDA: Grew by 1.9% to \$3.802 billion.
• Operating Cash Flow: Jumped 22.0% to \$2.014 billion.
• Same Facility Admissions: Up 0.9%; Same Facility Equivalent Admissions up 1.3%.
• Share Repurchases: 3.157 million shares repurchased at a cost of \$1.571 billion.
• Quarterly Dividend: \$0.78 per share declared, payable June 30, 2026.

Key Operational Insights

• Admissions and Volumes:
  • Same facility emergency room visits increased 0.3%.
  • Inpatient surgeries declined 0.3% and outpatient surgeries declined 1.7%.
  • Revenue per equivalent admission increased 3.1%.
  • The company did not experience the usual seasonal volume increase, mainly due to a 42% drop in respiratory-related admissions and a 32% drop in respiratory-related ER visits, attributed to lower respiratory activity and a winter storm in January.
• Balance Sheet and Cash Position:
  • As of March 31, 2026: Cash and cash equivalents at \$940 million.
  • Total assets: \$61.450 billion; Total debt: \$48.023 billion.
  • Capital expenditures in the quarter: \$1.119 billion (excluding acquisitions).
  • Availability under credit facility: \$4.336 billion.
• Share Repurchases and Capital Returns:
  • 3.157 million shares repurchased for \$1.571 billion in Q1 2026.
  • \$9.179 billion remains under repurchase authorization as of March 31, 2026.
• Dividend Policy:
  • Quarterly cash dividend of \$0.78/share declared, payable June 30, 2026, to shareholders of record as of June 16, 2026.
  • Future dividends are expected to be funded by cash balances and ongoing operating cash flows.

2026 Guidance Reaffirmed

• HCA reaffirms its 2026 guidance issued in January 2026:
  • Revenue: \$76.5 billion to \$80.0 billion for the full year 2026.
  • Net Income Attributable to HCA Healthcare, Inc.: \$6.495 billion to \$7.035 billion.
  • Adjusted EBITDA: \$15.550 billion to \$16.450 billion.
  • Diluted EPS: \$29.10 to \$31.50, based on 223.5 million shares outstanding.
• Guidance relies on assumptions of mostly stable operating environment, payer mix, and stable policy environment. Excludes impacts from potential gains/losses on sales, legal claims, and yet-to-be-approved Medicaid reimbursements.

Risks, Forward-Looking Statements, and Potential Price-Sensitive Factors

• Volume and Revenue Sensitivity: Notable drop in respiratory-related admissions and lack of typical seasonal volume increase. These were largely offset by recognition of certain Medicaid supplemental payments not originally expected in 2026 guidance—potentially a non-recurring benefit.
• Shareholder Returns: Aggressive share repurchases and robust dividend underscore management’s confidence in cash flow, but also reduce the share count, boosting EPS.
• Guidance Risks: Guidance is subject to multiple risks, including changes in health policy, expiration of enhanced premium tax credits at the end of 2025, inflation, payer mix shifts, labor cost increases, and potential federal government actions (e.g., spending reductions, Medicare/Medicaid reimbursement changes).
• Operational Efficiency Initiatives: HCA is pursuing technology and resilience initiatives, including AI and machine learning, to drive efficiencies and improve patient outcomes. Execution and results from these initiatives could impact future earnings and margin.
• Debt/Leverage: HCA’s significant debt load (\$48 billion) and upcoming maturities require careful monitoring, especially if market conditions or interest rates change.
• Market Risks: Potential for labor shortages, competitive pressures, changes in service mix, and macroeconomic or policy shocks.

Detailed Operating Statistics (Q1 2026 vs. Q1 2025)

• Admissions: 580,258 (up 0.7%)
• Equivalent Admissions: 1,023,575 (up 1.1%)
• Revenue per Equivalent Admission: \$18,669 (up 3.1%)
• Inpatient Revenue per Admission: \$20,297 (up 4.9%)
• Inpatient Surgeries: 133,262 (down 0.4%)
• Outpatient Surgeries: 240,061 (down 2.7%)
• Emergency Room Visits: 2,509,083 (down 0.4%)
• Patient Days: 2,774,607 (down 2.2%)
• Average Length of Stay: 4.782 days (down from 4.922)
• Occupancy: 75.5% (down from 76.9%)

Non-GAAP Measures

HCA emphasizes Adjusted EBITDA and adjusted earnings per share as key internal and external benchmarks. These metrics are widely used by management and investors to evaluate ongoing performance, but they are non-GAAP and may not be comparable to similar metrics from other companies. Notably, Q1 2026 Adjusted EBITDA margin declined slightly to 19.9% (vs. 20.4% in Q1 2025), reflecting some margin pressure.

Outlook and Investor Considerations

• HCA’s strong cash flow, continued share repurchases, and increased dividend are positive signals for shareholders.
• Reaffirmed guidance, despite some operating headwinds, signals management’s confidence in underlying business performance.
• However, flat-to-modest growth in admissions and surgical volumes, and the reliance on non-recurring Medicaid payments, may temper enthusiasm if volume growth does not accelerate in future quarters.
• Investors should monitor policy developments, especially around Medicaid, Medicare, and the expiration of enhanced premium tax credits, as these could significantly impact results.
• Any further share repurchase activity or changes to dividend policy could be price-sensitive, as could major changes in volumes, payer mix, or cost structure.

Conclusion

HCA Healthcare delivered a solid Q1 2026, with revenue growth, increased EPS, and robust cash flow. However, the quarter was marked by atypical volume patterns, and some earnings benefits were due to one-time Medicaid payments. The company’s reaffirmed full-year guidance and shareholder-friendly capital returns are positives, but investors should remain attentive to evolving risks in policy, labor costs, and healthcare utilization trends.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. The information is based on the company’s official filings and may be subject to change. Investors should conduct their own research and consult with professional advisors before making investment decisions.

View HCA Healthcare, Inc. Historical chart here